UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  October 21, 2022

Myovant Sciences Ltd.
 
(Exact name of registrant as specified in its charter)

001-37929
(Commission File Number)

Bermuda
98-1343578
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
     
7th Floor
 
50 Broadway
 
London
 
SW1H 0DB
 
United Kingdom
Not Applicable
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: +44 207 400 3351

Suite 1, 3rd Floor
11-12 St. James’s Square
London, SW1Y 4LB, United Kingdom
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Shares, par value $0.000017727 per share
MYOV
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07
Submission of Matters to a Vote of Security Holders.
 
On October 21, 2022, Myovant Sciences Ltd. (the “Company”) held its 2022 Annual General Meeting of Shareholders (the “Annual Meeting”) in London, United Kingdom. At the Annual Meeting, the shareholders considered and approved three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on July 28, 2022 (the “Proxy Statement”). Set forth below are the voting results with respect to each matter voted upon.
 
Proposal No. 1, Election of Directors: Terrie Curran, Mark Guinan, Adele Gulfo, David Marek, Shigeyuki Nishinaka, Myrtle Potter, and Nancy Valente, M.D. were each elected to serve as a director for a one-year term by the following votes:

Name
  
 
Votes For
  
Votes
Against
  
 
Abstain
  
 
Broker Non-Votes
Terrie Curran
  
66,247,643
  
8,847,106
  
31,189
  
10,083,977
Mark Guinan
  
74,542,690
  
552,518
  
30,730
  
10,083,977
Adele Gulfo
  
62,528,003
  
12,565,075
  
32,860
  
10,083,977
David Marek
  
64,265,380
  
10,829,226
  
31,332
  
10,083,977
Shigeyuki Nishinaka
  
62,316,646
  
12,780,642
  
28,650
  
10,083,977
Myrtle Potter
  
62,402,073
  
12,696,196
  
27,669
  
10,083,977
Nancy Valente, M.D.
  
73,411,611
  
1,682,126
  
32,201
  
10,083,977
 
Proposal No. 2, Ratification of Selection of Auditors: The shareholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending March 31, 2023, the appointment of Ernst & Young LLP as the Company’s auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for the Company’s fiscal year ending March 31, 2023, and the authorization of the Company’s Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as the Company’s auditor for the Company’s fiscal year ending March 31, 2023, by the following votes:
 
Votes For
  
Votes Against
  
Abstain
  
Broker Non-Votes
84,745,917
  
447,265
  
16,733
  
—
 
Proposal No. 3, Advisory Approval of Executive Compensation: The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as described in the Proxy Statement, by the following votes:

Votes For
  
Votes Against
  
Abstain 
 
Broker Non-Votes
68,808,308
  
5,909,941
  
407,689
  
10,083,977

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   
Myovant Sciences Ltd.
     
Date:
October 21, 2022
By:
/s/  Matthew Lang
   
Name:
Matthew Lang
   
Title:
General Counsel and Corporate Secretary